recommendations from the public. Once the PIN is finalized, it will be made available on HRSA's Web site, along with the Agency's "Response to Public Comments." That document will summarize the major comments received and describe the Agency's response, including any corresponding changes made to the PIN. Where comments do not result in a revision to the PIN, explanations will be provided.

### Background

HRSA administers the Health Center Program, which supports more than 3,800 health care delivery sites, including community health centers, migrant health centers, health care for the homeless centers, and public housing primary care centers. Health centers serve clients that are primarily low-income and minorities, and deliver preventive and primary care services to patients regardless of their ability to pay. Charges for health care services are set according to income.

FTCA medical malpractice coverage for Health Center Program grantees was initially legislated through the Federally Supported Health Centers Assistance Act (FSHCAA) of 1992. The FSHCAA of 1995 clarified the 1992 Act and eliminated its sunset provision, making the program permanent. FSCHAA authorizes Health Center Program grantees (and their officers, directors, employees, and certain contractors) to be deemed as Federal employees for the purpose of medical malpractice protection. As Federal employees, these organizations and individuals are immune from medical malpractice suits for actions within the scope of their project and employment. In the event that a medical malpractice lawsuit is filed against a deemed entity or covered physician acting within the scope of his/her employment in grant-related activities, the United States is substituted for the deemed entity and the covered employee.

HRSA recognizes that, during an emergency, FTCA-deemed health centers are likely to participate in medical response efforts. HRSA has received numerous requests for clarification regarding the scope of FTCA coverage during emergencies. The purpose of the FTCA PIN is to respond to these requests for clarification and to address frequently asked FTCA questions.

**FOR FURTHER INFORMATION CONTACT:** For questions regarding this notice, please contact Shannon Dunne Faltens at 301–594–4060.

Dated: March 29, 2007.

#### Elizabeth M. Duke,

Administrator.

[FR Doc. E7-6366 Filed 4-4-07; 8:45 am]

BILLING CODE 4165-15-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the Public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Molecular Oncology P01 Special Emphasis Panel.

Date: June 4–5, 2007.

Time: 8 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Michael B. Small, PhD, Scientific Review Administrator, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8127, Bethesda, MD 20892–8328, 301–402–0996, smallm@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Cellular and Tissue Biology (SEP).

Date: June 4–5, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Bethesda North Conference Center, 5701 Marinelli Road, Bethesda, MD 20852

Contact Person: Shakeel Ahmad, PhD, Scientific Review Administrator, Research Projects Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8137, MSC 8328, Bethesda, MD 20892, (301) 594–0114, ahmads@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Prevention, Control and Population Science.

Date: June 7, 2007. Time: 8 a.m. to 4 p.m. Agenda: To review and evaluate grant applications.

Place: Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Wlodek Lopaczynski, MD, PhD, Scientific Review Administrator, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd. Room 8131, Bethesda, MD 20892, 301–593–1402, lopacw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.303, Cancer Cause and Prevention

Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 27, 2007.

### Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–1694 Filed 4–4–07; 8:45 am] **BILLING CODE 4140–01–M** 

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

## National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the Public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group; Subcommittee A—Cancer Centers.

Date: April 24, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Gail J. Bryant, MD., Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8107, MSC 8328, Bethesda, MD 20892–8328, (301) 402–0801, gb30t@nih.gov.